{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:08:12Z","timestamp":1781683692858,"version":"3.54.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Children with recurrent hepatoblastoma have a poor prognosis and limited treatment options. The authors describe a child with metastatic hepatoblastoma who had multiple relapses. He was treated with surgical resection and adjuvant chemotherapy at first relapse. At second relapse, he had progressive disease postresection. He was treated with ifosfamide\/carboplatin\/etoposide chemotherapy followed by maintenance irinotecan and achieved long-term disease-free survival. Irinotecan as maintenance should be explored in recurrent hepatoblastoma.<\/jats:p>","DOI":"10.1097\/mph.0000000000001544","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T13:18:34Z","timestamp":1561727914000},"page":"e659-e661","source":"Crossref","is-referenced-by-count":5,"title":["Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma"],"prefix":"10.1097","volume":"42","author":[{"given":"Eesha","family":"Natarajan","sequence":"first","affiliation":[{"name":"Byramjee JeejeeBhoy Medical College, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Auerbach","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Cheron","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Pashankar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale University School of Medicine, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/pbc.24219","article-title":"Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies","volume":"59","author":"Trobaugh-Lotrario","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pbc.24218","article-title":"Relapsed hepatoblastoma","volume":"59","author":"Trobaugh-Lotrario","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MPH.0000000000000474","article-title":"Outcomes of patients with relapsed hepatoblastoma enrolled on Children\u2019s Oncology Group (COG) Phase I and II Studies","volume":"38","author":"Trobaugh-Lotrario","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.30591","article-title":"Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children\u2019s Oncology Group AHEP0731 study committee","volume":"123","author":"Katzenstein","year":"2017","journal-title":"Cancer"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1097-0142(20001015)89:8<1845::AID-CNCR27>3.0.CO;2-D","article-title":"Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors","volume":"89","author":"Perilongo","year":"2000","journal-title":"Cancer"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/1097-0142(19930201)71:3<859::AID-CNCR2820710333>3.0.CO;2-T","article-title":"Treatment of pulmonary metastases of initial stage I hepatoblastoma in childhood. Report from the Children\u2019s Cancer Group","volume":"71","author":"Feusner","year":"1993","journal-title":"Cancer"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jpedsurg.2007.08.030","article-title":"Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma","volume":"42","author":"Meyers","year":"2007","journal-title":"J Pediatr Surg"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-2007-964873","article-title":"The relevance of surgical therapy for bilateral and\/or multiple pulmonary metastases in children","volume":"17","author":"Hacker","year":"2007","journal-title":"Eur J Pediatr Surg"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/0022-3468(91)90678-M","article-title":"Aggressive excision of pulmonary metastases is warranted in the management of childhood hepatic tumors","volume":"26","author":"Black","year":"1991","journal-title":"J Pediatr Surg"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/mpo.2950240113","article-title":"Prolonged survival following multiple thoracotomies for metastatic hepatoblastoma","volume":"24","author":"Passmore","year":"1995","journal-title":"Med Pediatr Oncol"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1200\/JCO.2006.09.7204","article-title":"Redefining the role of doxorubicin for the treatment of children with hepatoblastoma","volume":"26","author":"Malogolowkin","year":"2008","journal-title":"J Clin Oncol"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children\u2019s Oncology Group Study","volume":"25","author":"Bomgaars","year":"2007","journal-title":"J Clin Oncol"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma\u2014a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zsiros","year":"2012","journal-title":"Eur J Cancer"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/08880018.2014.909913","article-title":"Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience","volume":"32","author":"Zhang","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/pbc.22408","article-title":"Irinotecan as maintenance therapy in high-risk hepatoblastoma","volume":"54","author":"Qayed","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/1097-0142(19950615)75:12<2966::AID-CNCR2820751226>3.0.CO;2-W","article-title":"Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors: response and toxicity","volume":"75","author":"Van Hoff","year":"1995","journal-title":"Cancer"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pbc.10375","article-title":"Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide\/carboplatin\/etoposide (ICE): a phase II study in a Pediatric Oncology Centre in Brazil","volume":"42","author":"Loss","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA2","article-title":"Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): a report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)","volume":"36(suppl abstr)","author":"Bisogno","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:23:01Z","timestamp":1696274581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001544","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,27]]}}}